These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Author: Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.
    Journal: Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891.
    Abstract:
    Small lymphocytic lymphoma (SLL) is considered as the non-leukemic form of presentation of chronic lymphocytic leukemia (CLL). We have compared the features, genomic alterations, and outcome of 890 patients with CLL and SLL. One hundred and thirteen patients presented as SLL and more frequently had unmutated-IGHV, CD38high, ZAP-70high, CD49dhigh, +12, alterations in genes of NOTCH1, cell cycle, RNA metabolism, and NFkB pathways than CLL. During the follow-up, 46% of SLL patients developed CLL. Time to first treatment (TTFT) was shorter in SLL (10-year: 75% vs 62%; p = .006). Binet stage, SLL, and IGHV were independent predictive factors for TTFT. Transformation to diffuse large B-cell lymphoma was higher (10-year: 12% vs 6%; p = .003), and overall survival was shorter in SLL (10-year: 55% vs 66%; p = .004). When A0 CLL patients were excluded, only CD38 and CD49d expression, +12, and 10-year TTFT remained different between the SLL and CLL patients. In summary, SLL showed only minor clinicobiological differences when compared with CLL in similar clinical stages.
    [Abstract] [Full Text] [Related] [New Search]